Abstract
Very Low Calorie Diets (VLCD) have been demonstrated to achieve rapid and significant weight loss in obese people without kidney disease. However, there is no published evidence on the use of VLCD in end-stage kidney disease (ESKD) patients. Current manufacturers’ guidelines state the meal replacement VLCD are contra-indicated in patients with impaired kidney function (eGFR <60ml/min). The aim of the study is to determine if the use of a VLCD with 3 meal replacements is safe and effective for weight loss in patients with ESKD treated with haemodialysis (HD).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
